Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 870

1.

Publisher Correction: Butler enables rapid cloud-based analysis of thousands of human genomes.

Yakneen S, Waszak SM; PCAWG Technical Working Group, Gertz M, Korbel JO; PCAWG Consortium.

Nat Biotechnol. 2020 Feb 12. doi: 10.1038/s41587-020-0448-9. [Epub ahead of print]

PMID:
32051562
2.

Butler enables rapid cloud-based analysis of thousands of human genomes.

Yakneen S, Waszak SM; PCAWG Technical Working Group, Gertz M, Korbel JO; PCAWG Consortium.

Nat Biotechnol. 2020 Feb 5. doi: 10.1038/s41587-019-0360-3. [Epub ahead of print] Erratum in: Nat Biotechnol. 2020 Feb 12;:.

PMID:
32024987
3.
4.

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Gertz MA, Kumar SK.

Am J Hematol. 2020 Feb 3. doi: 10.1002/ajh.25746. [Epub ahead of print]

PMID:
32010993
5.

Utility of serum free light chain ratio in response definition in patients with multiple myeloma.

Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2020 Jan 28;4(2):322-326. doi: 10.1182/bloodadvances.2019001099. No abstract available.

6.

Non-transplant eligible multiple myeloma: deciphering optimal first line regimens.

Vaxman I, Gertz M.

Leuk Lymphoma. 2020 Mar;61(3):504-506. doi: 10.1080/10428194.2020.1716223. Epub 2020 Jan 24. No abstract available.

PMID:
31975634
7.

Waldenstrom's macroglobulinemia in the era of immunotherapy.

Vaxman I, Gertz M.

Leuk Lymphoma. 2020 Jan 21:1-13. doi: 10.1080/10428194.2020.1711901. [Epub ahead of print]

PMID:
31960730
8.

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.

Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A.

Blood Cancer J. 2020 Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9.

9.

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G.

J Neurol. 2020 Jan 6. doi: 10.1007/s00415-019-09688-0. [Epub ahead of print] Review.

PMID:
31907599
10.

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.

Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2020 Mar;95(3):310-315. doi: 10.1002/ajh.25709. Epub 2020 Jan 8.

PMID:
31867775
11.

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.

Coelho T, Yarlas A, Waddington-Cruz M, White MK, Sikora Kessler A, Lovley A, Pollock M, Guthrie S, Ackermann EJ, Hughes SG, Karam C, Khella S, Gertz M, Merlini G, Obici L, Schmidt HH, Polydefkis M, Dyck PJB, Brannagan Iii TH, Conceição I, Benson MD, Berk JL.

J Neurol. 2019 Dec 18. doi: 10.1007/s00415-019-09671-9. [Epub ahead of print]

PMID:
31853709
12.

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.

Tschautscher M, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell S, Leung N, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S.

Am J Hematol. 2020 Mar;95(3):E60-E62. doi: 10.1002/ajh.25702. Epub 2019 Dec 30. No abstract available.

PMID:
31840857
13.

Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.

Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S.

Blood Rev. 2019 Dec 5:100648. doi: 10.1016/j.blre.2019.100648. [Epub ahead of print] Review.

14.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.

Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P.

Am J Hematol. 2020 Mar;95(3):274-281. doi: 10.1002/ajh.25697. Epub 2019 Dec 31.

PMID:
31814157
15.

Alterations in sick dairy cows' daily behavioural patterns.

Dittrich I, Gertz M, Krieter J.

Heliyon. 2019 Nov 22;5(11):e02902. doi: 10.1016/j.heliyon.2019.e02902. eCollection 2019 Nov. Review.

16.

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.

Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves WI, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, Lacy MQ, Buadi FK, Leung N, Kyle RA, Kumar SK, King RL, Gertz MA.

Leukemia. 2019 Nov 28. doi: 10.1038/s41375-019-0667-6. [Epub ahead of print]

PMID:
31780812
17.

Revisiting complete response in light chain amyloidosis.

Sidana S, Dispenzieri A, Murray DL, Go RS, Buadi FK, Lacy MQ, Gonsalves WI, Dingli D, Warsame R, Kourelis T, Muchtar E, Hayman SR, Kapoor P, Kyle RA, Leung N, Rajkumar SV, Gertz MA, Kumar SK.

Leukemia. 2019 Nov 26. doi: 10.1038/s41375-019-0664-9. [Epub ahead of print] No abstract available.

PMID:
31772296
18.

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A.

Leukemia. 2019 Nov 22. doi: 10.1038/s41375-019-0655-x. [Epub ahead of print]

PMID:
31758090
19.

New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Vaxman I, Dispenzieri A, Muchtar E, Gertz M.

Blood Rev. 2019 Nov 2:100636. doi: 10.1016/j.blre.2019.100636. [Epub ahead of print] Review.

PMID:
31706583
20.

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.

Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):53-56. doi: 10.1016/j.clml.2019.09.624. Epub 2019 Oct 9.

PMID:
31685378
21.

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.

Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2020 Jan;95(1):4-9. doi: 10.1002/ajh.25657. Epub 2019 Oct 29.

PMID:
31612526
22.

Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.

Al Saleh AS, Sidiqi MH, Gertz MA, Muchtar E, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Buadi FK, Dispenzieri A, Dingli D, Kumar SK.

Am J Hematol. 2020 Jan;95(1):E8-E10. doi: 10.1002/ajh.25654. Epub 2019 Oct 21. No abstract available.

PMID:
31591735
23.

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23.

PMID:
31544536
24.

Management of induction failures in newly diagnosed transplant-eligible multiple myeloma.

Gertz MA.

Leuk Lymphoma. 2020 Jan;61(1):1-3. doi: 10.1080/10428194.2019.1663424. Epub 2019 Sep 10. No abstract available.

PMID:
31502884
25.

Joint Pain and Proteinuria.

Al Saleh AS, Sidiqi MH, Gertz MA.

JAMA. 2019 Sep 5. doi: 10.1001/jama.2019.12704. [Epub ahead of print] No abstract available.

PMID:
31486835
26.

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.

Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P.

Br J Haematol. 2020 Feb;188(3):394-403. doi: 10.1111/bjh.16168. Epub 2019 Aug 29.

PMID:
31468508
27.

The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

Gonzalez Suarez ML, Zhang P, Nasr SH, Sathick IJ, Kittanamongkolchai W, Kurtin PJ, Alexander MP, Cornell LD, Fidler ME, Grande JP, Herrera Hernandez LP, Said SM, Sethi S, Dispenzieri A, Gertz MA, Leung N.

Kidney Int. 2019 Oct;96(4):1005-1009. doi: 10.1016/j.kint.2019.05.027. Epub 2019 Jun 25.

PMID:
31447055
28.

How I treat cold agglutinin hemolytic anemia.

Gertz MA.

Clin Adv Hematol Oncol. 2019 Jun;17(6):338-343. No abstract available.

PMID:
31437137
29.

Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Gertz MA, Mauermann ML, Grogan M, Coelho T.

Brain Behav. 2019 Sep;9(9):e01371. doi: 10.1002/brb3.1371. Epub 2019 Aug 1. Review.

30.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486. No abstract available.

PMID:
31343331
31.

Therapy of Transthyretin Cardiomyopathy.

Gertz MA.

J Am Coll Cardiol. 2019 Jul 23;74(3):296-298. doi: 10.1016/j.jacc.2019.05.031. No abstract available.

PMID:
31319911
32.

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA, Frankel AE.

Acta Haematol. 2019 Jul 16:1-6. doi: 10.1159/000500976. [Epub ahead of print] Review.

33.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Dec;187(5):588-594. doi: 10.1111/bjh.16096. Epub 2019 Jul 12.

PMID:
31298751
34.

Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis.

Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Wolf RC, Kapoor P, Buadi FK, Kumar SK, Gertz MA.

Am J Hematol. 2019 Oct;94(10):1066-1071. doi: 10.1002/ajh.25572. Epub 2019 Jul 23.

PMID:
31273808
35.

Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy.

Al Saleh AS, Sidiqi MH, Gertz MA.

Mayo Clin Proc. 2019 Jul;94(7):1380-1381. doi: 10.1016/j.mayocp.2019.04.023. No abstract available.

PMID:
31272581
36.

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):701-711. doi: 10.1080/17512433.2019.1635008. Epub 2019 Jul 3. Review.

PMID:
31268366
37.

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.

Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA.

Am J Hematol. 2019 Sep;94(9):1020-1026. doi: 10.1002/ajh.25566. Epub 2019 Jul 11.

PMID:
31254301
38.

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J.

Cancer. 2019 Oct 15;125(20):3574-3581. doi: 10.1002/cncr.32357. Epub 2019 Jun 28.

PMID:
31251390
39.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

40.

Correction: Waldenström macroglobulinemia treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2019 Jun 25;9(7):53. doi: 10.1038/s41408-019-0212-x.

41.

The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2019 Dec;54(12):2039-2050. doi: 10.1038/s41409-019-0590-5. Epub 2019 Jun 12.

42.

Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis.

Venkatesh SK, Hoodeshenas S, Venkatesh SH, Dispenzieri A, Gertz MA, Torbenson MS, Ehman RL.

J Clin Med. 2019 May 23;8(5). pii: E739. doi: 10.3390/jcm8050739.

43.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 Dec;60(12):2960-2967. doi: 10.1080/10428194.2019.1613536. Epub 2019 May 16.

PMID:
31096812
44.

Burden of hereditary transthyretin amyloidosis on quality of life.

Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, Lovley A, Kessler AS, Patel PA, White MK, Guthrie SD.

Muscle Nerve. 2019 Aug;60(2):169-175. doi: 10.1002/mus.26515. Epub 2019 Jun 13.

45.

Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1520-1525. doi: 10.1016/j.bbmt.2019.04.024. Epub 2019 May 2.

PMID:
31054986
46.

Multiple myeloma and kidney transplantation: the beginning of a new era.

Van den Bosch I, Sprangers B, Gertz M.

Clin Kidney J. 2019 Mar 1;12(2):213-215. doi: 10.1093/ckj/sfz003. eCollection 2019 Apr.

47.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

48.

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

Sidiqi MH, Nadiminti K, Al Saleh AS, Meleveedu K, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2019 Nov;54(11):1775-1779. doi: 10.1038/s41409-019-0524-2. Epub 2019 Apr 8.

PMID:
30962503
49.

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Jul;94(7):751-756. doi: 10.1002/ajh.25481. Epub 2019 Apr 30.

PMID:
30945330
50.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

Supplemental Content

Support Center